Literature DB >> 30612811

Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents.

Anna Neyman1, John S Fuqua2, Erica A Eugster2.   

Abstract

PURPOSE: The purpose of the study was to describe the novel use of bicalutamide in transgender youth.
METHODS: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children.
RESULTS: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III.
CONCLUSIONS: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.
Copyright © 2018 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bicalutamide; Gender dysphoria; Puberty blocker; Transgender care

Year:  2019        PMID: 30612811      PMCID: PMC6431559          DOI: 10.1016/j.jadohealth.2018.10.296

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  6 in total

1.  Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.

Authors:  Daniele Tessaris; Patrizia Matarazzo; Alessandro Mussa; Gerdi Tuli; Francesca Verna; Ludovica Fiore; Roberto Lala
Journal:  Endocr J       Date:  2011-11-09       Impact factor: 2.349

2.  Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.

Authors:  Wylie C Hembree; Peggy T Cohen-Kettenis; Louis Gooren; Sabine E Hannema; Walter J Meyer; M Hassan Murad; Stephen M Rosenthal; Joshua D Safer; Vin Tangpricha; Guy G T'Sjoen
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

3.  Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT).

Authors:  Edward O Reiter; Nelly Mauras; Ken McCormick; Bindu Kulshreshtha; James Amrhein; Francesco De Luca; Sandra O'Brien; Jon Armstrong; Helena Melezinkova
Journal:  J Pediatr Endocrinol Metab       Date:  2010-10       Impact factor: 1.634

4.  Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism.

Authors:  J C Prior; Y M Vigna; D Watson
Journal:  Arch Sex Behav       Date:  1989-02

5.  Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.

Authors:  Anne M Lenz; Dorothy Shulman; Erica A Eugster; Samar Rahhal; John S Fuqua; Ora H Pescovitz; Katherine A Lewis
Journal:  Pediatrics       Date:  2010-08-16       Impact factor: 7.124

6.  Health Concerns of Transgender and Gender Nonconforming Youth and Their Parents Upon Presentation to a Transgender Clinic.

Authors:  Shauna M Lawlis; Hillary R Donkin; Justin R Bates; Maria T Britto; Lee Ann E Conard
Journal:  J Adolesc Health       Date:  2017-09-01       Impact factor: 5.012

  6 in total
  5 in total

Review 1.  Challenges in the care of transgender and gender-diverse youth: an endocrinologist's view.

Authors:  Stephen M Rosenthal
Journal:  Nat Rev Endocrinol       Date:  2021-08-10       Impact factor: 43.330

2.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

Review 3.  The Care of Transgender Young People.

Authors:  Damian Krebs; Rebecca M Harris; Alyssa Steinbaum; Sarah Pilcher; Carly Guss; Jessica Kremen; Stephanie A Roberts; Charumathi Baskaran; Jeremi Carswell; Kate Millington
Journal:  Horm Res Paediatr       Date:  2022-03-10       Impact factor: 4.275

4.  Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.

Authors:  Mark Lieber; Matthew M Hamill; Paul Pham; Elyse Pine; Jill Crank; Maunank Shah
Journal:  Open Forum Infect Dis       Date:  2022-03-23       Impact factor: 3.835

5.  Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents.

Authors:  Michele A O'Connell; Thomas P Nguyen; Astrid Ahler; S Rachel Skinner; Ken C Pang
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.